• Saracatinib (AZD0530) in Cancer Biology: Pathway Dissection

  2026-04-22

  Explore how Saracatinib (AZD0530) transforms cancer biology research by enabling precise dissection of Src/Abl signaling and advanced cell migration assays. This in-depth article reveals unique protocol guidance and translational insights not covered in existing resources.

• Robust Reporter Assays with EZ Cap™ mCherry mRNA (5mCTP, ψUT

  2026-04-22

  This article addresses persistent challenges in cell-based assays—such as inconsistent fluorescent reporter expression and innate immune activation—by exploring the practical advantages of EZ Cap™ mCherry mRNA (5mCTP, ψUTP) (SKU R1017). Through real-world laboratory scenarios, we demonstrate how its advanced Cap 1 structure and nucleotide modifications deliver reproducible, high-sensitivity red fluorescent protein mRNA workflow outcomes.

• iPSC-Derived Airway Models Advance Cystic Fibrosis Drug Test

  2026-04-21

  This study develops a robust induced pluripotent stem cell (iPSC) platform to model airway disease in cystic fibrosis (CF), enabling precise, genotype-specific drug testing for both common and rare CFTR variants. The platform’s multimodal assay approach reveals distinct functional responses to CFTR modulators, paving the way for personalized and accelerated therapeutic development.

• Acifran: Selective GPR109A/B Agonist for Lipid Metabolism Re

  2026-04-21

  Acifran, also known as (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a verified selective agonist for HM74A/GPR109A and GPR109B, supporting advanced lipid metabolism research. Its structural selectivity and well-characterized receptor interactions make it an essential tool for dissecting lipid signaling pathways in metabolic disorder research.

• Triiodothyronine (T3): Precision Tools for Metabolic Pathway

  2026-04-20

  Triiodothyronine (T3) from APExBIO empowers metabolic and thyroid hormone signaling studies with unmatched purity and reproducibility. This article delivers actionable protocols, advanced use-cases, and expert troubleshooting to maximize T3’s impact in cellular and metabolic research.

• Imidazoline Antagonists Enhance Insulin Release via K+ Chann

  2026-04-20

  This study demonstrates that imidazoline antagonists of α2-adrenoceptors increase insulin secretion from pancreatic β-cells primarily by inhibiting ATP-sensitive potassium (K+) channels, rather than through adrenoceptor blockade. The findings clarify a key mechanism underlying insulinotropic effects of these compounds and support more precise pharmacological targeting in diabetes research.

• Axitinib (AG 013736): Reliable VEGFR Inhibition in Cancer As

  2026-04-19

  This article provides an evidence-based, scenario-driven guide to leveraging Axitinib (AG 013736) (SKU A8370) for robust angiogenesis inhibition and tumor growth studies. Addressing common laboratory challenges, we synthesize quantitative data, best practices, and vendor selection insights to support reproducible results in cancer biology research.

• Y-27632: Targeting ROCK Signaling in Metastatic Cancer Model

  2026-04-18

  Explore the advanced use of Y-27632, a selective ROCK inhibitor, in dissecting cytoskeletal modulation and metastatic mechanisms in cancer biology. This article uniquely bridges molecular pharmacology with experimental design, providing actionable insights for ROCK pathway research.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-04-17

  Anlotinib hydrochloride redefines angiogenesis and cancer research by offering unparalleled selectivity and potency as a multi-target tyrosine kinase inhibitor. Its robust inhibition of VEGFR2, PDGFRβ, and FGFR1, paired with favorable pharmacokinetics and minimal cytotoxicity, enables reproducible, data-driven workflows for both endothelial biology and tumor models.

• Nintedanib (BIBF 1120): Precision Angiokinase Inhibition for

  2026-04-16

  Explore the distinct antiangiogenic profile of Nintedanib (BIBF 1120) in advanced cancer models and idiopathic pulmonary fibrosis. This article provides a deep-dive into mechanistic insights, protocol optimization, and actionable guidance for translational research.

• Re-Evaluating ACE Inhibitors: Selectivity Among Aminopeptida

  2026-04-15

  This study systematically compares the inhibitory profiles of bestatin and multiple ACE inhibitors against key mammalian cell-surface aminopeptidases, revealing distinct selectivity patterns and potential off-target effects. The findings refine our understanding of ACE inhibitor specificity, informing experimental design in hypertension and cardiovascular research.

• DAPI (hydrochloride): Precision DNA Visualization & Protocol

  2026-04-14

  DAPI (hydrochloride) is a DNA-specific fluorescent probe that binds to A-T rich regions, enabling reliable chromosome staining, cell cycle analysis, and DNA visualization in histochemistry. Its high specificity and compatibility with both fixed and live cells make it a benchmark dye for nuclear imaging. This article details its mechanism, validated use cases, and integration best practices for research workflows.

• Gene Expression Profiling Predicts PARP Inhibitor Response i

  2026-04-13

  Borchert et al. (2019) systematically profiled homologous recombination repair (HRR) pathway gene expression in malignant pleural mesothelioma (MPM), showing that defects termed 'BRCAness' identify tumors more likely to respond to PARP inhibition. Their findings suggest that HRR profiling can refine therapeutic stratification and support novel combination strategies in MPM [source_type: paper][source_link: https://doi.org/10.1186/s12885-019-5314-0].

• SAR405: Precision Vps34 Inhibitor for Autophagy Research

  2026-04-12

  SAR405 empowers researchers to dissect autophagy and vesicle trafficking with nanomolar precision. Its selectivity and compatibility with mTOR inhibition make it a superior tool for probing disease mechanisms and energy stress responses in cell models.

• SCH772984 HCl: Applied Protocols for ERK1/2 Inhibition in Ca

  2026-04-12

  SCH772984 HCl from APExBIO empowers researchers with precision control over ERK1/2 signaling, enabling reproducible dissection of MAPK pathway resistance in BRAF- and RAS-mutant cancer models. This guide translates cutting-edge findings into actionable protocols and troubleshooting strategies for advanced oncology and stem cell research.

16788 records 1/1120 page Next 12345 下5页 Last page